The FDA said the warning label of drugs known as gonadotropin-releasing hormone agonists, used for treating prostate cancer, will mention a potential risk of diabetes and heart disease. The agency previously disclosed that six studies demonstrated a "small increased risk of diabetes and/or cardiovascular disease" among prostate cancer patients using hormone therapy.

Related Summaries